A July 2024 study published in JAMA Ophthalmology revealed that diabetic patients who take semaglutide have a hazard ratio of 4.28 for developing nonarteritic anterior ischemic optic neuropathy (NAION)meaning their risk is over four times greater than patients on other diabetes drugs
Duration of Study: Tirzepatide study duration has varied from 24 to 72 weeks
A recently published survey conducted among Israeli endocrinologists, internal medicine physicians and family physicians who practice obesity medicine reported that fewer than 50% of physicians discussed treatment duration with their patients, and 52% of patients discontinued therapy in the first 3 months
News provided by Novo Nordisk Aug 18, 2025, 09:00 ET Offer supports access for eligible patients without insurance to FDA-approved Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, the GLP-1 medicine with the broadest range of FDA-approved indications for adults with type 2 diabetes 1 For the first time, Ozempic is available via home delivery through NovoCare Pharmacy
doi: 10.1111/nph.12468 107 Van De MortelJ
If side effects dont lessen after a few weeks, talk to your provider about dose adjustments